Adam Oskowitz
YOU?
Author Swipe
View article: Spatial Transcriptomics Reveals <i>CXCL12</i> ⁺ Fibroblasts as Central Immune Organizers through CXCR4 Signaling in Abdominal Aortic Aneurysm
Spatial Transcriptomics Reveals <i>CXCL12</i> ⁺ Fibroblasts as Central Immune Organizers through CXCR4 Signaling in Abdominal Aortic Aneurysm Open
BACKGROUND Abdominal aortic aneurysm (AAA) is characterized by sterile inflammation, immune cell infiltration, and stromal remodeling that progressively weaken the aortic wall, leading to life-threatening aortic rupture. The molecular mech…
View article: <i>Ex Vivo</i> Expanded Regulatory T Cells Inhibit AAA Progression by Limiting CD4+ and CD8+ T Cell Accumulation in Aortic Tissue
<i>Ex Vivo</i> Expanded Regulatory T Cells Inhibit AAA Progression by Limiting CD4+ and CD8+ T Cell Accumulation in Aortic Tissue Open
Background Regulatory T cells (Tregs) play a crucial role in the pathophysiology of abdominal aortic aneurysms (AAA), a chronic inflammatory condition with few treatment options for patients with early-stage disease. Treg therapy for AAA i…
View article: Supplementary Table S4 from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy
Supplementary Table S4 from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy Open
Supplementary Table S4: The %IA/g values for biodistribution (4 days p.i.) of [89Zr]DFO-YS5 in C42B-Luc disseminated tumor models performed at 9 weeks post inoculations of cells.
View article: Supplementary Table S9 from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy
Supplementary Table S9 from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy Open
Supplementary Table S9: Biodistribution of [89Zr]DFO-YS5 in the mice from late treatment study (week 3 post inoculations) treated with 4.6 and 9.2 kBq of [225Ac]Macropa-PEG4-YS5.
View article: Data from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy
Data from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy Open
Purpose:Metastatic castration-resistant prostate cancer has limited treatment options and a poor prognosis. Recently, prostate-specific membrane antigen (PSMA)-targeted alpha-particle therapy agents using actinium-225 (225Ac) ha…
View article: Supplementary Table S8 from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy
Supplementary Table S8 from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy Open
Supplementary Table S8: The %IA/g values for biodistribution of [89Zr]DFO-YS5 in the mice from early treatment (week 1 post inoculations) treated with 4.2 and 9.2 kBq of [225Ac]Macropa-PEG4-YS5.
View article: Supplementary Table S3 from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy
Supplementary Table S3 from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy Open
Supplementary Table S3: The %IA/g values for biodistribution (4 days p.i.) of [89Zr]DFO-YS5 in 5-week-old DU145-Luc disseminated tumor models.
View article: Supplementary Table S1 from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy
Supplementary Table S1 from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy Open
Supplementary Table S1: The %IA/g values for biodistribution (4 days p.i.) of [89Zr]DFO-YS5 in 22Rv1-Luc disseminated tumor models performed at week 5 post inoculations.
View article: Supplementary Table S6 from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy
Supplementary Table S6 from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy Open
Supplementary Table S6: The %IA/g values for biodistribution of [89Zr]DFO-YS5 in 22Rv1-luc tumor models at week 3 post intracardiac injections.
View article: Supplementary Figure S1-S34 from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy
Supplementary Figure S1-S34 from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy Open
Supplementary Figure S1-S34
View article: Supplementary Table S5 from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy
Supplementary Table S5 from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy Open
Supplementary Table S5: The %IA/g values for biodistribution of [89Zr]DFO-YS5 in 22Rv1-luc tumor models at week 1 post intracardiac injections.
View article: Supplementary Table S7 from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy
Supplementary Table S7 from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy Open
Supplementary Table S7: The %IA/g values for biodistribution of [225Ac]Macropa-PEG4-YS5 in 22Rv1-luc tumor models at week 3 post intracardiac injections.
View article: Supplementary Table S2 from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy
Supplementary Table S2 from Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted <sup>225</sup>Ac Therapy Open
Supplementary Table S2: The %IA/g values for biodistribution study of [89Zr]DFO-YS5 in PC3-Luc disseminated tumors, conducted 4 days post-injection (p.i.), utilized mice with PC3-Luc tumors at 5 weeks post-cell inoculations. The large inte…
View article: Toward the Autonomous AI Doctor: Quantitative Benchmarking of an Autonomous Agentic AI Versus Board-Certified Clinicians in a Real World Setting
Toward the Autonomous AI Doctor: Quantitative Benchmarking of an Autonomous Agentic AI Versus Board-Certified Clinicians in a Real World Setting Open
Background: Globally we face a projected shortage of 11 million healthcare practitioners by 2030, and administrative burden consumes 50% of clinical time. Artificial intelligence (AI) has the potential to help alleviate these problems. How…
View article: Impact of Emergency Department Presentation for Chronic Limb-threatening Ischemia on Limb Loss Rates in a Public Safety Net Population
Impact of Emergency Department Presentation for Chronic Limb-threatening Ischemia on Limb Loss Rates in a Public Safety Net Population Open
View article: Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy
Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy Open
Purpose: Metastatic castration-resistant prostate cancer has limited treatment options and a poor prognosis. Recently, prostate-specific membrane antigen (PSMA)-targeted alpha-particle therapy agents using actinium-225 (225Ac) have shown p…
View article: Supplementary Figure S14 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S14 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Figure S14. Autoradiographic images and H&E staining images of PDX LTL-545 tumor sections from day 1 to day 4 post injection of 89Zr labeled nanocarriers.
View article: Supplementary Table S15 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S15 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Table S15. Organ biodistribution analysis data in %ID/g tissue for 89Zr labeled nanocarriers at 96 h in metastatic mice model with 22rv1 cell inoculated in kidney capsule tumors. (n = 4)
View article: Supplementary Figure S16 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S16 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Figure S16. (a) White light images of LTL-610 tumors, and the respective (b) autoradiographic images of tumor sections on day 4 post injection of [89Zr]PEG-DFB4.
View article: Supplementary Figure S12 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S12 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Figure S12. Autoradiographic images and H&E staining images of subcutaneous 22rv1 tumor sections from day 1 to day 4 post injection of 89Zr labeled nanocarriers. *Indicate the presence of necrosis.
View article: Supplementary Figure S9 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S9 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Figure S9. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ for 89Zr labeled nanocarriers in nude mice bearing CT26 subcutaneous tumors at 96 h postinjection. (n = 5, mean ± SD)
View article: Supplementary Table S8 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S8 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Table S8. Organ biodistribution analysis data in %ID/g tissue for 89Zr labeled nanocarriers at 96 h in mice model bearing CT26 subcutaneous tumors. (n = 5)
View article: Supplementary Table S5 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S5 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Table S5. Region of interest analysis data reported as %ID/cc of the [89Zr]PEG-DFB1-TLZ3 on on different subcutaneous tumors from Day 1-4 post injection. (n = 4)
View article: Supplementary Table S9 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S9 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Table S9. Organ biodistribution analysis data in %ID/Organ tissue for 89Zr labeled nanocarriers at 96 h in mice model bearing CT26 subcutaneous tumors. (n = 5)
View article: Supplementary Figure S5 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S5 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Figure S5. Coronal μPET/CT fusion and MIP images obtained at 24 h, 48 h, 72 h, and 96 h following administration of 150-170 μCi of 89Zr labeled nanocarriers in nude mice bearing CT26 subcutaneous tumors over left flanks.
View article: Supplementary Table S13 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S13 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Table S13. Organ biodistribution analysis data in %ID/Organ tissue for 89Zr labeled nanocarriers at 96 h in mice model bearing LTL-610 subcutaneous tumors. (n = 4)
View article: Supplementary Figure S1 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S1 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Figure S1. (a) Zeta potential of the StarPEG conjugates PEG-DFB4 and PEG-DFB1-TLZ3 with an average surface charge of -4.04±0.21 mV and -1.41±0.22 mV, respectively (n = 3). (b) TEM images of PEG-DFB4 and PEG-DFB1-TLZ3 showing …
View article: Supplementary Figure S20 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S20 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Figure S20. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ of [89Zr]PEG-DFB1-TLZ3 in nude mice inoculated with 22rv1 cells in the left kidney capsule at 96 h postinjection. (n = 4, mean ± SD)
View article: Supplementary Table S17 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S17 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Table S17. Organ biodistribution analysis data in %ID/g tissue for 89Zr labeled nanocarriers at 72 h in nude mice inoculated with 22rv1 cells via intracardiac injection. (n = 4)
View article: Supplementary Table S18 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S18 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Table S18. Organ biodistribution analysis data in %ID/Organ tissue for 89Zr labeled nanocarriers at 72 h in nude mice inoculated with 22rv1 cells via intracardiac injection. (n = 4)